Please use this identifier to cite or link to this item:
Scopus Web of ScienceĀ® Altmetric
Full metadata record
DC FieldValueLanguage
dc.contributor.authorCheng, A.-
dc.contributor.authorTurnidge, J.-
dc.contributor.authorCollignon, P.-
dc.contributor.authorLooke, D.-
dc.contributor.authorBarton, M.-
dc.contributor.authorGottlieb, T.-
dc.identifier.citationEmerging Infectious Diseases, 2012; 18(9):1453-1460-
dc.description.abstractFluoroquinolone antimicrobial drugs are highly bioavailable, broad-spectrum agents with activity against gram-negative pathogens, especially those resistant to other classes of antimicrobial drugs. Australia has restricted the use of quinolones in humans through its national pharmaceutical subsidy scheme; and, through regulation, has not permitted the use of quinolones in food-producing animals. As a consequence, resistance to fluoroquinolones in the community has been slow to emerge and has remained at low levels in key pathogens, such as Escherichia coli. In contrast to policies in most other countries, this policy has successfully preserved the utility of this class of antimicrobial drugs for treatment of most infections.-
dc.description.statementofresponsibilityAllen C. Cheng, John Turnidge, Peter Collignon, David Looke, Mary Barton, and Thomas Gottlieb-
dc.publisherCenter Disease Control-
dc.rightsCopyright status unknown-
dc.subjectAnti-Bacterial Agents-
dc.subjectDrug Resistance, Bacterial-
dc.subjectGovernment Regulation-
dc.subjectDrug and Narcotic Control-
dc.subjectDrug Prescriptions-
dc.titleControl of fluoroquinolone resistance through successful regulation, Australia-
dc.typeJournal article-
dc.identifier.orcidTurnidge, J. [0000-0003-4240-5578]-
Appears in Collections:Aurora harvest
Molecular and Biomedical Science publications

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.